TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05438979

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison to CFB

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Fructoborate
Description: 216mg CFB
Study: NCT05814315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE Intervention
Description: Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
Study: NCT05772676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + standard antiemetic regimen, once two hours before surgery
Study: NCT06008119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tunlametinib plus Vemurafenib
Description: 12mg BID Tunlametinib+720mg BID Vemurafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
Description: According to investigators' suggestion
Study: NCT04868019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate Capsules
Description: Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate Capsules
Description: Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
Study: NCT05278741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for unilateral breast reconstruction
Description: Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months, six months and 12 months: 2 questionnaires + two tests will be perfomed
Study: NCT05419713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Stimuli for Space Perception
Description: The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
Study: NCT06047756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Patient will perform different movement of the trunk while sitting on a horse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swiss Ball therapy
Description: Patient will perform movements of trunk on swiss ball
Study: NCT06474923

Intervention type: BEHAVIORAL
Intervention: Face image and voice audio
Description: Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.

Intervention type: BEHAVIORAL
Intervention: Face image and voice audio
Description: Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.
Study: NCT06273280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Physician-guided GDMT up-titration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized up-titration
Description: Renal-based protocolized GDMT up-titration
Study: NCT05003024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF SCAN
Description: For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~Once 2 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 2 mg/kg sugammadex will be injected. Train of four ratio (delivered every minute) will be recorded.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITF
Description: For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~On the ITF device side, 3 minutes after sugammadex administration, a tetanus 100 Hz stimulation will be done followed 2 minutes later by a tetanus 50 Hz stimulation.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
Study: NCT05788627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: Oral lactulose in a dose of 30ml BD and tap water enema 1000ml BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral lactulose in a dose of 30ml BD and lactulose enema (300ml lactulose and 700ml water) in a dose of 1000ml BD.
Study: NCT06047574

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions
Study: NCT05842642

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical
Description: 6 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical
Description: 6 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor
Description: 6 weeks of treatment
Study: NCT05293405

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 18F-DPA-714 PET
Description: TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DPA-714 PET
Description: TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET
Study: NCT06507280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal theraphy
Description: periodontal therapy
Study: NCT05069636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic OMM
Description: Patients receive lymphatic myofascial release and thoracic pump techniques.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch
Description: Patients receive a series of light touch techniques.
Study: NCT06283862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Session
Description: The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Session
Description: The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
Study: NCT05034731

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote Fitting
Description: Processors will be programmed using remote fitting application.

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote Fitting
Description: Processors will be programmed using remote fitting application.

Intervention type: DEVICE
Group type: OTHER
Intervention: In-Office Fitting
Description: Processors will be programmed using standard Target CI application.

Intervention type: DEVICE
Group type: OTHER
Intervention: In-Office Fitting
Description: Processors will be programmed using standard Target CI application.
Study: NCT02097446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardix-FL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interceed
Study: NCT04760067

Intervention type: OTHER
Intervention: Sports Injury Anxiety Scale
Description: Sports Injury Anxiety Scale

Intervention type: OTHER
Intervention: Sports Injury Anxiety Scale
Description: Sports Injury Anxiety Scale

Intervention type: OTHER
Intervention: Sports Injury Anxiety Scale
Description: Sports Injury Anxiety Scale
Study: NCT06483659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous Oxytocin infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study: NCT05310565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVLA cervical chiropractic adjustments
Description: Chiropractic high velocity low amplitude adjustment
Study: NCT05101928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex 0.7mg Ophthalmic Implant
Description: A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
Study: NCT05179746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implants are decontaminated with electrolytic cleaning
Description: Implants are decontaminated with electrolytic cleaning

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implants are decontaminated without electrolytic cleaning
Description: Implants are decontaminated without electrolytic cleaning
Study: NCT05653947

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root canal instrumentation, 2.5% NaOCl irrigation
Description: Root canal instrumentation, 2.5% NaOCl irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal instrumentation, 2.5% NaOCl irrigation
Description: Root canal instrumentation, 2.5% NaOCl irrigation
Study: NCT05860569

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC304
Description: Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC304
Description: Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC304
Description: Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
Study: NCT05625724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Experimental drug administrated orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for the control group
Study: NCT05986981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects).
Study: NCT06518733

Intervention type: OTHER
Intervention: appliance type
Description: different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews

Intervention type: OTHER
Intervention: appliance type
Description: different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews

Intervention type: OTHER
Intervention: appliance type
Description: different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews

Intervention type: OTHER
Intervention: appliance type
Description: different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews

Intervention type: OTHER
Intervention: appliance type
Description: different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews
Study: NCT05060575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and Telephone Counceling
Description: Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Telephone Counceling
Description: Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes.
Study: NCT02653911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Hwato Brand, Suzhou Medical Appliance Factory, China

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture group
Description: Hwato Brand, Suzhou Medical Appliance Factory, China
Study: NCT05204147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT04878315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capoten
Description: Capoten will be administered per the treatment sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capoten
Description: Capoten will be administered per the treatment sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capoten
Description: Capoten will be administered per the treatment sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Captopril will be administered per the treatment sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Captopril will be administered per the treatment sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Captopril will be administered per the treatment sequence
Study: NCT05620277

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with cross-polarization filter
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobile Dental Photography with cross-polarization filter and gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with cross-polarization filter
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with cross-polarization filter and gray reference card
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital Camera with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rayplicker
Description: Tooth color changes of 30 patients will be evaluated using Rayplicker

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rayplicker with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vita Easyshade
Description: Tooth color changes of 30 patients will be evaluated using Vita Easyshade

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vita Easyshade with gray reference card
Description: Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
Study: NCT04792177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation skills training
Description: The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
Study: NCT05772182

Intervention type: DEVICE
Intervention: ACORYS MAPPING SYSTEM
Description: Diagnostic Test: ECG-Imaging~Diagnostic Test: Standard 12-lead ECG~Diagnostic Test: Endocardial mapping and/or pacing
Study: NCT05419622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bronchial biopsies
Description: This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
Study: NCT05554211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
Study: NCT05431764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, gemcitabin, cisplatin
Description: Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
Description: IMRT: 5 fractions per week for 6 weeks to a total dose of 70 Gy and 33 fractions to the primary tumor.~SBRT: 3 months after locoregional IMRT, patients receive SBRT for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.~Camrelizumab (200mg, iv drip for over 60min) every 2 weeks began on the first day of IMRT until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years.